Notably, the subsequent settlement between Novo Nordisk and Hims & Hers (under which Hims & Hers will sell branded FDA-approved semaglutide products while ceasing its advertising of compounded alternatives) suggests that at least some market participants are already adapting to this new reality
Roundhill GLP-1 & Weight Loss ETF Today OZEM Roundhill GLP-1 & Weight Loss ETF $32.48 +0.26 (+0.81%) As of 07/24/2026 03:47 PM Eastern 52-Week Range $23.22 $37.15 Much of that growth can be attributed to the recent performances of the aforementioned three Big Pharma companiesNovo Nordisk, Eli Lilly, and Pfizerwhich together account for almost 40% of the ETFs total weighting, with NVO and LLY receiving the two largest allocations overall
Higher doses start at $299 to $349 for a onemonth prescription under Foundayo's self-pay program
It transfers the reducing power of cytosolic NADH to the mitochondrial electron transport chain (ETC) via the glycerolphosphate shuttle [31, 32]
Add a drizzle of honey if you need sweetness
Instead of relying solely on pricey brand-name drugs, incorporate compounded versions of GLP-1s as a safe, affordable alternative